Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab^*

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;21361:2066–2078.
   Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389:1741–1755.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
   PubMed Web of Science ®Google Scholar
• Dignass A, Assche G, Van Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn’s Colitis. 2010;4:28–62.
   Google Scholar
• Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics. 2011;29:387–401.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005;2:493.
   PubMedGoogle Scholar
• Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–545.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• D’Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010;7:86–92.
   PubMed Web of Science ®Google Scholar
• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322–337.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.
   PubMed Web of Science ®Google Scholar
• Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol. 2012;26:811–817.
   PubMed Web of Science ®Google Scholar
• Pillai N, Dusheiko M, Burnand B, et al. A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One. 2017;12:e0185500.
   PubMed Web of Science ®Google Scholar
• Valk MVD, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut England. 2014;63:72–79.
   PubMed Web of Science ®Google Scholar
• Valk MVD, Mangen MJ, Severs M, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11:e0142481.
   PubMed Web of Science ®Google Scholar
• Nurmi E, Haapamäki J, Paavilainen E, et al. The burden of inflammatory bowel disease on health care utilization and quality of life. Scand J Gastroenterol. 2013;48:51–57.
   PubMed Web of Science ®Google Scholar
• Brochures of the Ministry of Social Affairs and Health. Health Care in Finland. Finland: Ministry of Social Affairs and Health. 2013.
   Google Scholar
• Jussila A, Virta LJ, Kautiainen H, et al. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555–561.
   PubMed Web of Science ®Google Scholar
• Jussila A, Virta LJ, Salomaa V, et al. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. J Crohn’s Colitis. 2013;7:e256–e262.
   Google Scholar
• Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974–982.
   PubMed Web of Science ®Google Scholar
• Aladul MI, Fitzpatrick RW, Chapman SR. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: results of a budget impact analysis. Res Social Adm Pharm. 2019;15:310–317.
   PubMed Web of Science ®Google Scholar
• Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. Inflamm Bowel Dis England. 2015;21:121–131.
   PubMed Web of Science ®Google Scholar
• Stone CD. The economic burden of inflammatory bowel disease: clear problem, unclear solution. Dig Dis Sci. 2012;57:3042–3044.
   PubMed Web of Science ®Google Scholar
• Vasudevan A, Gibson PR, Langenberg DV. Systematic review: cost-effective strategies of optimizing anti-tumor necrosis and immunomodulators in inflammatory bowel disease. Inflamm Bowel Dis England. 2019 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Carter CT, Leher H, Smith P, et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care. 2011;17:385–392.
   PubMed Web of Science ®Google Scholar
• Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs. Adv Ther. 2011;28:671–683.
   PubMed Web of Science ®Google Scholar
• Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3:63–68.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn's disease. Ther Adv Gastroenterol. 2010;3:179–189.
   PubMedGoogle Scholar
• Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Heal Q. 2018;7:3.
   PubMedGoogle Scholar
• Elenko E, Underwood L, Zohar D. Defining digital medicine. Nat Biotechnol. 2015;33:456–461.
   PubMed Web of Science ®Google Scholar